Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
NTLA Stock Chart & Stats
$15.44
-$0.56(-4.53%)
At close: 4:00 PM EST
$15.44
-$0.56(-4.53%)
Day’s Range― - ―
52-Week Range$5.90 - $28.25
Previous CloseN/A
Volume723.92K
Average Volume (3M)4.62M
Market Cap
$1.82B
Enterprise Value$1.73B
Total Cash (Recent Filing)$449.88M
Total Debt (Recent Filing)$93.33M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Apr 30, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding118,133,545
10 Day Avg. Volume2,507,717
30 Day Avg. Volume4,622,721
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue25.51
Enterprise Value/Gross Profit-99.83
Enterprise Value/Ebitda-4.13
Forecast
1Y Price Target
$21.17Price Target Upside37.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)-3.62
Revenue Forecast (FY)$56.93M
Bulls Say, Bears Say
Bulls Say
Clinical Trial Enrollment And AdoptionRapid enrollment and strong U.S. participation in the HAELO program signal patient and physician willingness to adopt a one-time therapy over chronic alternatives, supporting upside in market penetration if approved.
Commercial Launch PotentialA Phase III readout for the hereditary angioedema program and progress toward a biologics license application position lonvo-z as a potential near-term commercial catalyst if safety and efficacy are confirmed.
Regulatory Clearance For Trial ResumptionFDA removal of the clinical hold on the pivotal MAGNITUDE-2 study after agreement on enhanced liver monitoring and stricter patient screening enables enrollment and dosing to resume under a clearer regulatory pathway for nex-z.
Bears Say
Cardiomyopathy Regulatory UncertaintyThe larger MAGNITUDE cardiomyopathy trial remaining on clinical hold creates material regulatory uncertainty for the company’s leading value driver, which could constrain valuation until regulatory clarity is achieved.
Development Cost And Timeline RiskPotential requirements for expanded safety datasets, larger trials, and enhanced monitoring for higher-risk cardiac patients would increase development costs and extend the timeline to potential approval and launch.
Liver Safety SignalSerious liver safety events, including a Hy’s Law case associated with a patient death, remain a material overhang that could reduce clinician confidence and limit patient uptake even after trials restart.
Intellia Therapeutics News
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $5.90 and its highest was $28.25 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.82B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 57 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$0.955 by $0.125.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -0.92.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 118,133,545 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$0.83 in its last earnings report, beating expectations of -$0.955. Following the earnings report the stock price went up 6.408%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in NTLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.17 (37.11% Upside)
$21.17 (37.11% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 813.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $906.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Bullish
Bullish news 77%
Bearish news 23%
Bearish news 23%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.88%
12-Months-Change
Fundamentals
Return on Equity
-53.48%
Trailing 12-Months
Asset Growth
-29.29%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
NTLA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of important clinical and commercial progress — most notably the completed Phase 3 enrollment and upcoming pivotal readout for lonvo-z, strong patient and physician interest, durable early efficacy signals, and improved near-term financial metrics — alongside meaningful risks: a still-pending FDA hold on the large cardiomyopathy ATTR program driven by serious liver enzyme events (including one patient death), material year-over-year cash depletion, and incomplete understanding of the safety signal’s mechanism and breadth. Management has secured a partial regulatory win (MAGNITUDE-2 hold lifted with specific mitigations) and emphasizes preparedness for a potential lonvo-z launch, but the unresolved MAGNITUDE hold and safety uncertainty inject non-trivial downside risk.View all NTLA earnings summariesNTLA Revenue Breakdown
100.00% Collaboration revenue
NTLA Stock 12 Month Forecast
Average Price Target
$21.17
▲(37.11% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―
Ownership Overview
1.82% Insiders
16.50% Mutual Funds
21.81% Other Institutional Investors
29.90% Public Companies and Individual Investors